Montelukast for Early Life Wheezing

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Massachusetts, Worcester
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Physician-diagnosed wheezing illness

Exclusion Criteria:

• Asthma

• Prematurity

• Known intolerance to montelukast